Welcome to our dedicated page for LeMaitre Vascular news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on LeMaitre Vascular stock.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) is a leading provider of medical devices and implants for the treatment of peripheral vascular disease, a condition that affects over 200 million people globally. The company develops, manufactures, and markets disposable and implantable vascular devices aimed at addressing the needs of vascular surgeons. LeMaitre Vascular offers a diversified product portfolio that includes angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems.
Headquartered in Burlington, Massachusetts, LeMaitre's products are utilized during open vascular surgeries, primarily focusing on several anatomical areas such as the carotid, lower extremities, upper extremities, and aorta. The company's lower extremities product line generates the highest revenue, followed by the carotid product line. In recent financial updates, the company reported significant growth in sales across various product categories including bovine patches, valvulotomes, and carotid shunts.
LeMaitre Vascular continues to demonstrate robust financial health. For Q3 2023, the company reported a 21% increase in sales and a 49% rise in operating income, driven by price increases and operational efficiencies. Operating income for Q4 2023 was up 46%, reflecting strong sales growth and improved gross margins. In addition, LeMaitre has a share repurchase program and regularly pays dividends to its shareholders, exemplifying its commitment to shareholder value.
Furthermore, LeMaitre Vascular is focused on expanding its global footprint. Sales in the Americas, EMEA, and APAC regions have shown substantial growth, contributing significantly to the company's revenue. The company also emphasizes compliance with global regulatory requirements, ensuring that its products meet stringent quality standards.
LeMaitre frequently engages with investors through earnings calls, providing transparency about its financial performance and strategic outlook. The company remains committed to innovation and development, constantly working on new projects to enhance its product offerings and address emerging market needs.
For more information about LeMaitre Vascular and its latest updates, visit their official website at www.lemaitre.com.
LeMaitre (NASDAQ: LMAT) reported its Q1 2022 results, highlighting a sales increase of $39.6 million, up 10% year-over-year. Operating income remained flat at $7.9 million with a 20% operating margin. The company announced a quarterly dividend of $0.125 per share and provided updated guidance for 2022, forecasting sales of $160-$164 million. Key developments included a buyout of its Korean distributor and the closure of its St. Etienne factory, expected to reduce future operating costs. However, the strong U.S. dollar negatively impacted both sales and operating income guidance.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced it will release its Q1 2022 financial results on April 28, 2022, post-market. A conference call is scheduled for 5:00 PM ET to discuss the results and company outlook. LeMaitre specializes in devices and services for treating peripheral vascular disease, impacting over 200 million globally. The company develops and markets both disposable and implantable vascular devices targeted at vascular surgeons. Further details can be found at www.lemaitre.com.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced that Chief Financial Officer JJ Pellegrino will present at the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 10:15 AM ET. LeMaitre specializes in devices and services for treating peripheral vascular disease, impacting over 200 million globally. The company focuses on developing disposable and implantable vascular devices tailored for vascular surgeons.
LeMaitre (Nasdaq:LMAT) has been added to the NASDAQ US Broad Dividend Achievers Index, recognizing companies with a decade of increasing dividends. Since initiating dividends in 2011, LeMaitre's payout per share rose from $0.08 to $0.44 in 2021, achieving an 18.6% compounded annual growth rate. A new quarterly dividend of $0.125 will be distributed on March 24, 2022. CEO George W. LeMaitre emphasized the company's commitment to profitability and an improved balance sheet through consistent dividend increases.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in four significant investor conferences this March. The 34th Annual Roth Conference is scheduled for March 14, 2022, with President David Roberts presenting. Following that, the Oppenheimer 32nd Annual Healthcare Conference takes place on March 16, 2022, featuring CFO JJ Pellegrino. On March 17, 2022, Roberts will present at the Barclays Global Healthcare Conference, and the month concludes with the KeyBanc Life Sciences & MedTech Investor Forum on March 22, 2022.
LeMaitre (Nasdaq:LMAT) reported Q4 2021 sales of $39.5 million, a 5% increase year-over-year, driven by higher sales of bovine grafts and patches. Operating income fell 13% to $8.3 million, with an operational margin of 21%. The company announced a 14% increase in its quarterly dividend to $0.125 per share, marking the 11th consecutive year of dividend growth. For Q1 2022, guidance suggests sales between $37.7 million and $39.7 million, with a gross margin of 66.2%. Full-year 2022 guidance anticipates sales of $162 million to $166 million, aiming for an EPS of $1.35 to $1.45.
LeMaitre Vascular, Inc. (LMAT) will release its fourth quarter 2021 financial results on February 24, 2022, after market close. A conference call is scheduled for 5:00 PM ET that day to discuss the results and company outlook. The company provides devices and services for peripheral vascular disease, affecting over 200 million people globally. Investors can access the live call by dialing 800-773-2954 or through a webcast on the company's investor relations website.
LeMaitre Vascular announced that CFO JJ Pellegrino will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 10:30 AM ET. The company specializes in devices and services for treating peripheral vascular disease, impacting over 200 million people globally. LeMaitre develops and markets both disposable and implantable vascular devices tailored for vascular surgeons. More information is available at www.lemaitre.com.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced that CFO JJ Pellegrino will present at the 24th Annual Needham Virtual Growth Conference on January 14, 2022, at 3:30 PM. The company specializes in devices and services for treating peripheral vascular disease, which affects over 200 million people globally. LeMaitre develops a range of disposable and implantable vascular devices aimed at meeting the needs of vascular surgeons. Additional details are available on their website at www.lemaitre.com.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) has announced participation in three upcoming virtual investor conferences:
- Stifel 2021 Virtual Healthcare Conference – November 15, 2021, 8:40 AM ET (David Roberts, President)
- Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum – November 18, 2021 (JJ Pellegrino, CFO)
- Piper Sandler 33rd Virtual Annual Healthcare Conference – November 29 – December 2, 2021 (Pre-recorded presentation by David Roberts)
LeMaitre specializes in medical devices for peripheral vascular disease, serving over 200 million affected patients globally.
FAQ
What is the current stock price of LeMaitre Vascular (LMAT)?
What is the market cap of LeMaitre Vascular (LMAT)?
What products does LeMaitre Vascular offer?
Where is LeMaitre Vascular headquartered?
In which medical areas are LeMaitre's products primarily used?
What was the company's financial performance in Q3 2023?
How does LeMaitre Vascular engage with its investors?
What regions contribute significantly to LeMaitre's revenue?
Does LeMaitre Vascular pay dividends to its shareholders?
What recent financial achievements has LeMaitre Vascular reported?
How does LeMaitre ensure the quality of its products?
Where can I find more information about LeMaitre Vascular?
